KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition

Sorafenib, a multikinase inhibitor, is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, resistance to this regimen is frequently observed in clinical practice, and the molecular basis of this resistance remains largely unknown. Herein, the antitumor activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bo, Cheng, Jian-Wen, Hu, Jin-Wu, Li, Hong, Ma, Xiao-Lu, Tang, Wei-Guo, Sun, Yun-Fan, Guo, Wei, Huang, Ao, Zhou, Kai-Qian, Gao, Ping-Ting, Cao, Ya, Qiu, Shuang-Jian, Zhou, Jian, Fan, Jia, Yang, Xin-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692625/
https://www.ncbi.nlm.nih.gov/pubmed/31417635
http://dx.doi.org/10.7150/jca.31448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692625/
https://www.ncbi.nlm.nih.gov/pubmed/31417635
http://dx.doi.org/10.7150/jca.31448

Ejemplares similares